ABSTRACT Recently, increasing experimental studies have shown that microRNAs (miRNAs) involved in multiple physiological processes are connected with several complex human diseases. Identifying human disease-related miRNAs will be useful in uncovering novel prognostic markers for cancer. Currently, several computational approaches have been developed for miRNA-disease association prediction based on the integration of additional biological information of diseases and miRNAs, such as disease semantic similarity and miRNA functional similarity. However, these methods do not work well when this information is unavailable. In this paper, we present a similarity-based miRNA-disease prediction method that enhances the existing association discovery methods through a topology-based similarity measure. DeepWalk, a deep learning method, is utilized in this paper to calculate similarities within a miRNA-disease association network. It shows superior predictive performance for 22 complex diseases, with area under the ROC curve scores ranging from 0.805 to 0.937 by using five-fold cross-validation. In addition, case studies on breast cancer, lung cancer, and prostatic cancer further justify the use of our method to discover latent miRNA-disease pairs.
I. INTRODUCTION
MicroRNAs (miRNAs), as a class of short non-coding RNA molecules (19∼24 nt), act as negative regulators of gene expression by binding to the 3'-UTRs of target mRNAs [1] , [2] . Recently, increasing evidence has indicated that mutation and functional disorders of miRNAs are connected with the development and progression of various complex human diseases [3] - [5] . Consequently, identifying disease-related miRNAs will be beneficial for investigating mechanisms of pathogenicity and promoting the diagnosis and treatment of human disease.
It has proved effective using biomedical technologies such as microarrays and PCR to identify the miRNAs associated with individual diseases. However, these biological experimental methods can be costly and time-consuming. Encouragingly, more and more experimentally verified disease-miRNA association databases have become available, for example, the Human miRNA Disease Database (HMDD) [6] and miR2Disease [7] . The establishment of these miRNA-related biological datasets has created a foundation for predictive research. Therefore, there exists a strong need to develop efficient computational models to predict new types of disease-related miRNAs on a large scale.
Many computational models have been put forward to excavate latent miRNA-disease associations, under the assumption that functionally similar miRNAs are likely to be linked with similar diseases, and vice versa [8] - [12] . For instance, Jiang et al. [13] introduced a computational model that integrates miRNA functional similarity data, phenotype similarity data, and experimentally verified diseasemiRNA association data to predict latent interactions between miRNAs and diseases by using a hypergeometric distribution. Unfortunately, the efficacy of this method was seriously restrained by predicted miRNA-target interactions with high false-positive and false-negative rates [14] , [15] . Xuan et al. [16] proposed a highly performing prediction algorithm called HDMP based on weighted k most similar neighbors, which computed miRNA functional similarity by utilizing semantic similarity and phenotype similarity data of their associated diseases. These aforementioned methods only considered local miRNA and disease information in their computational models but did not utilize global network association information, which can significantly enhance prediction performance. Thus, researchers have presented many global network similarity-based computational modes based on random walks. Chen et al. [17] developed the first global model called RWRMDA by performing random walks restarting on a constructed miRNA-miRNA functional similarity network to infer new miRNA-disease pairs. In addition, Shi et al. [18] used random walk analysis to rank miRNA-disease pairs by searching for functional associations between disease-related genes and miRNA targeted genes in a protein-protein interaction network. Similarly, Xuan et al. [19] presented another new model called MIDP based on random walks, which assigned different transition matrices to labeled and unlabeled miRNAs of a specific disease during the iterative process. Luo and Xiao [20] also introduced a novel approach that performed unbalanced birandom walks on bipartite subgraphs to identify diseasemiRNA interactions. Liu et al. [21] extended random walk with restart on a constructed heterogeneous network to infer the relationship between disease and miRNA. To further enhance the prediction accuracy, Chen et al. [22] developed a computational model named WBSMDA, which took advantage of within and between scores of each candidate disease-miRNA pair to discover disease-miRNA associations. WBSMDA improved disease semantic similarity and miRNA functional similarity by integrating Gaussian interaction profile kernel similarity. Recently, Chen et al. [23] has further proposed a heterogeneous graph-based model called HGIMDA, which infers the potential association likelihood of each candidate disease-miRNA pair by counting all routes of length three. In addition, some machine learning-based models have been proposed to identify latent relationships between diseases and miRNAs [24] , [25] . However, none of the above methods have satisfactory performance, and most of them rely on heterogeneous omics data. On the other hand, in a miRNA-disease bipartite network, each miRNA-disease pair is validated by biological experiments, which provides important prior information and produces direct benefits to the prediction of novel disease-miRNA pairs.
In this study, we propose a similarity-based miRNAdisease prediction method that adopts a deep learning algorithm, DeepWalk [26] , to extract features of vertices in the miRNA-disease bipartite network, which can be adapted to compute the topological similarities of two vertices [27] . The resulting similarity measure is used to infer disease-related miRNAs based on a rule-based inference method [28] that uses disease-disease similarities as the input for miRNA-disease prediction. The experimental results of five-fold cross-validation and case studies support the ability of our method to infer novel miRNA-disease pairs, which may be of great use in further biological experiments. 
II. MATERIALS AND METHODS

A. METHOD OVERVIEW
The method proposed in this study is based on the topological structure of a miRNA-disease bipartite network. The association discovery method can be separated into three steps: (i) data collection, (ii) similarity learning, and (iii) association discovery. First, a bipartite network containing the topological interactions of existing miRNAs and diseases is constructed. Second, similarity scores of disease-disease pairs are learned based on the topology of this network. Finally, predictions and evaluations of new disease-miRNA pairs are made based on these similarities. Fig. 1 illustrates the overall workflow of our method.
B. HUMAN miRNA-DISEASE ASSOCIATION DATASET
The disease-miRNA association dataset was downloaded from the HMDD v2.0 database. There were 5424 distinct experimentally confirmed associations between 378 diseases and 495 miRNAs after filtering out duplicate records. Briefly, the number of diseases and miRNAs are represented by variables nd and nm, respectively. In addition, two other public databases (i.e., dbDEMC [29] and PhenomiR2.0 [30] ) were adopted to assess the candidate miRNA predictions with case studies. VOLUME 5, 2017 C. SIMILARITY LEARNING DeepWalk [26] , a deep learning method, vectorizes the vertices (e.g., diseases and miRNAs) of the network for similarity computation. This method utilizes local information from truncated random walks to learn vertex representation by maximizing the probability of observing vertex v i in view of all vertices previously visited up to the current point in the random walk. DeepWalk has two main components. First, for each vertex v i , γ random walks with length t are conducted, with v i as the starting vertex. Second, for each walk, the vertex representation is updated with the SkipGram algorithm [31] . SkipGram maximizes the co-occurrence likelihood of the vertices that come into view within a window w using an independent assumption as follows:
where denotes the latent topological representation associated with each vertex v i . is represented by a |V |×d matrix, where |V | is the cardinality of vertex set V , and d is the dimension of the vertex vector. To speed up the training time, Pr(v j | (v i )) is factorized with Hierarchical Softmax [32] by allocating the vertices to the leaves of a binary tree, and Pr(v j | (v i )) is then computed as follows: After completing the training, the output of DeepWalk is a latent topological representation (i.e., d-dimensional vector) of vertices in the network. Therefore, the similarity of two vertices u and v can be computed by using cosine similarity as follows:
where d is the dimension, and u i and v i are the components of vector u and v, respectively.
D. DISEASE-BASED SIMILARITY INFERENCE
We adapted a rule-based inference method, drug-based similarity inference (DBSI) [28] , which was derived from complex network theory [33] to predict disease-related miRNA candidates with disease-disease similarities. The main idea of DBSI is as follows: if a disease is associated with a miRNA, then other diseases similar to that disease will also possibly be associated with the miRNA. In terms of the pair (d i , m j ), a linkage between disease d i and miRNA m j is decided by the following prediction score:
where sim(d i , d l ) is the similarity between disease d i and disease d l obtained from (3) , and a lj = 1 if an association between disease d l and miRNA m j is known; otherwise, a lj = 0.
Operationally, for a disease d i as the input query, each associated score is normalized as follows: 
III. EXPERIMENTS AND RESULTS
A. EVALUATION METRICS
To systematically evaluate the prediction accuracy of our method, five-fold cross-validation was implemented on the basis of disease-miRNA pairs obtained from the HMDD database. In the 5-fold cross validation framework, for a given disease d, the labeled d-associated miRNAs are partitioned into five disjoint subsections at random: one subsection is used for testing and the other four subsections for training through multiple iterations. The similarity computation for diseases is connected with known disease-miRNA pairs; thus, disease-disease similarities are recalculated in each repetition of the cross-validation experiments. The area under the ROC curve (AUC) was used to assess the quality of the predicted associations.
B. EFFECT OF PARAMETERS ON THE PERFORMANCE OF OUR METHOD
There are five parameters in DeepWalk. In this article, we fixed the window size w = 10 and the walk length t = 40 to highlight the local structure according to a previous study [26] . The three other parameters were determined by a grid search over the parameter ranges specified in previous work (i.e., dimension d = {32, 64, 128}, training rate α = {0.01, 0.05, 0.09}, and number of walks γ = {40, 80, 120, 160}) [26] . Here, to study the effect of these three parameters on the prediction accuracy, we varied the values of d, α, and γ in 5-fold cross-validation experiments. Fig. 2 presents the average AUC values obtained from our method for different values of d, α, and γ . As is shown in the figure, the best prediction performance is achieved at d = 64, α = 0.05, and γ = 120. Therefore, we set d = 64, α = 0.05, and γ = 120 as default values in our experiment.
C. PREDICTION PERFORMANCE EVALUATION
We compared our method with RWRMDA [17] , MIDP [19] , and WBSMDA [22] , which serve as advanced computational prediction models to discover potential candidate miRNAs. Since RWRMDA and MIDP were developed based on the association data from the previous version of HMDD, the similarity of diseases or miRNAs pairs was recalculated with the latest version of HMDD. Many diseases have connections with only a few miRNAs; hence, the performance of five-fold cross-validation may not be sufficient for them. Consequently, we only considered 22 diseases associated with at least 60 miRNAs, as confirmed by our experiments.
As is shown in Table 1 , our method achieves the best performance for all the 22 diseases except esophageal neoplasms and urinary bladder neoplasms, which performed better with MIDP and WBSMDA, respectively. The average AUC value achieved by our tool was 0.865, with a minimum of 0.805 for heart failure and a maximum of 0.937 for lung neoplasms, whereas the respective AUCs of RWRMDA, MIDP, and WBSMDA were 0.801, 0.833, and 0.829. The average AUCs obtained by our method were 6.4%, 3.2%, and 3.6% higher than those of the other three methods. The ROC curves of each method using five-fold cross-validation are shown in Fig. 3 .
Moreover, for purpose of comparison we select the top 10, top 30, top 50, top 80 and top 100 predicted associations for each disease as potential candidates. For these selections, VOLUME 5, 2017 the number of known disease-miRNA associations detected by our method and three other methods are shown in Fig. 4 . From Fig. 4 , we can see that the result of our method performs better than the other three algorithms in all selections, except in top 10 which is only slightly lower than that of MIDP. These prediction results illustrate that our method achieves reliable prediction performance, especially because our method only depends on the topological structure of the miRNA-disease bipartite network.
D. DEEPWALK-BASED VS. GAUSSIAN INTERACTION PROFILE KERNEL-BASED SIMILARITY MEASURES
We compared DeepWalk-based to Gaussian interaction profile kernel-based topology similarity measures [34] , predicting miRNA-disease association for the 22 aforementioned diseases. As for the latter, we first adopted the Gaussian kernel to compute the similarity of each disease-disease pair based on the topological structure of the miRNA-disease bipartite network. We then assembled similarity measures with the rule-based inference method, DBSI, to obtain the association probability of each candidate disease-miRNA pair. Fig. 5 illustrates that DeepWalk is superior to the method based on Gaussian kernel in terms of AUC for these diseases, except for acute myeloid leukemia. For example, the AUC scores achieved by DeepWalk for breast cancer, lung cancer, and prostatic cancer are 0.861, 0.937, and 0.888, respectively, whereas the respective AUCs obtained by Gaussian kernel are 0.810, 0.922, and 0.839. The comparison results also demonstrate that applying DeepWalk for similarity computation can improve prediction accuracy.
E. CASE STUDIES
Additionally, in an attempt to assess the ability of our method to uncover potential disease-associated miRNAs, case studies of three important complex human diseases were investigated by considering all known associations included in the HMDD database as a training set. The prediction-associated miRNAs for each selected disease were validated based on two independent databases, dbDEMC [29] and PhenomiR2.0 [30] , and experimental literature.
Particularly in developed countries, women's cancer deaths are primarily caused by breast cancer. Recently, accumulating evidence has shown that many miRNAs are related to the formation of diverse cancers comprised of breast neoplasms. For instance, hsa-mir-205 regulates ErbB3 by binding to its 3'-UTR, which is significantly under-expressed in breast tumors [35] . Discovering more miRNAs associated with breast cancer will aid in accurately assessing clinical results. The case study of breast neoplasms was implemented with our method. As a result, 14 and 26 out of the top 15 and top 30 potentially related miRNAs have been directly shown to be linked with breast neoplasms through dbDEMC and PhenomiR2.0 databases (see Table 2 ). Furthermore, some predicted miRNAs were verified by previously published literature. Specifically, hsa-mir-378a (6th in the prediction list) represses the expression of two genes in breast neoplasms, ERR γ and GABPA [36] . Hsa-mir-574 (18th in the prediction list) has been identified as a potentially novel prognostic indicator of breast cancer, which is significantly downregulated in tumor samples [37] . Hsa-mir-362 (19th in the prediction list) has been shown to be differentially expressed in MCF-7 human breast cancer cells [38] . It has also been shown that hsa-mir-542 (27th in the prediction list) is significantly down-regulated in breast cancer cells [39] .
Lung cancer is one of the pervasive malignant tumors with the highest mortality. The top 30 predicted lung neoplasm-associated miRNAs are listed in Table 3 . From the table, 15 out of the top 15 and 28 out of the top 30 potentially associated miRNAs were validated by the two aforementioned databases. In addition, the other two candidates are supported by published literature. Specifically, hsa-mir151a (16th in the prediction list) is markedly up-regulated in non-small cell lung carcinoma compared with non-tumorous tissue [40] . Hsa-mir-378a (19th in the prediction list) is significantly overexpressed in squamous cell carcinoma when compared with lung adenocarcinoma [41] .
Prostatic cancer is the second major cause of male cancerrelated deaths in developed countries. We implemented our method to prioritize candidate prostatic neoplasm-associated miRNAs, and results show that 13 and 26 out of the top 15 and top 30 predicted miRNAs were contained in dbDEMC and PhenomiR2.0 (see Table 4 ). Two candidates, hsa-mir-9 [42] and hsa-mir-138 [43] , were verified to be correlated with prostatic neoplasms by experimental literature. In addition, hsa-mir-429 (17th in the prediction list) is the second ranked miRNA by RWRMDA and Jiang's method. Hsa-mir-103a (19th in the prediction list) is ranked No. 3 by KRLSM [12] , which indirectly confirms that it is probably associated with prostatic cancer.
In summary, the results of cross-validation and case studies of several common diseases fully illustrate that our method achieves excellent prediction performance. Therefore, we have further used our method to rank potential miRNAs for each human disease contained in HMDD (shown in Supplementary Table S1), in the hope that these prediction results can be verified in future scientific research.
IV. CONCLUSION
Identifying novel miRNA-disease associations is important for exploring disease pathogenesis and to further improve human medicine. In this paper, a similarity-based method was designed to identify latent miRNA-disease pairs. First, we adopted a deep learning algorithm, DeepWalk, to determine the similarity of each disease-disease pair based on a known disease-miRNA bipartite network. Then, with a rulebased inference method, DBSI, similarity measures were assembled to compute the association likelihood of each candidate disease-miRNA pair. To validate the prediction accuracy of our approach, five-fold cross-validation was implemented with a miRNA-disease association dataset. In addition, case studies on breast cancer, lung cancer, and prostatic cancer were done, and 30, 30, and 28 of the top 30 predicted miRNAs for each of these three principal human diseases have been verified by the latest experimental literature and two independent databases.
Despite this successful exploitation of bipartite network topology through application of DeepWalk for similarity computation in miRNA-disease interaction prediction, there are also some inevitable limitations expected to be improved in future research. To begin with, the proposed method fails to predict associations for new diseases or miRNAs that do not exist within the network because our method is only informed by known miRNA-disease associations. To solve this problem, a hybrid similarity measure that includes both topological and non-topological features, like disease semantic similarity data and miRNA functional similarity data, may facilitate application of this methodology to predict new diseases or miRNAs. Second, the currently known miRNA-disease associations are insufficient. Therefore, a heterogeneous network that integrates additional disease-gene and miRNA-gene associations can be used for similarity learning, which may potentially improve prediction results. Finally, there are five parameters in our method, and the selection of appropriate parameters for different diseases needs to be properly addressed. 
